Plasma MicroRNA for Prediction of Hepatocellular Carcinoma

100 patients with diagnosed HCV were evaluated by clinical and ultrasound examination and were categorized as uncomplicated HCV (n=22) and complicated HCV (n=78). All patients were evaluated for hepatosteatosis and liver fibrosis using the computerized hepatorenal index, the hepatic steatosis index, aspartate aminotransferase (AST)/platelet count index (APRI) and the Fibrosis-4 (FIB-4) scores. Blood samples were obtained for estimation of serum levels of liver function tests and plasma levels of microRNA 21 and 126.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatitis C Blood-Borne Infections Communicable Diseases Digestive System Diseases Flaviviridae Infections Hepatitis Hepatitis, Viral, Human Infections Liver Diseases RNA Virus Infections Virus Diseases

Age range

31 year–67 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Benha university

Banhā, El- Qalyobia, 13511, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Complicated hepatitis C by HCC
Complicated hepatitis C by liver cirrhosis
Complicated hepatitis C by steatohepatitis
uncomplicated hepatitis C

Exclusion criteria

pre-portal fibrosis secondary to previous bilharzial disease
pre-portal fibrosis secondary to alcoholic fatty liver
The presence of hepatic malignancy other than HCC
decompensated cirrhosis
hepatorenal failure
hepatic manifestations of congestive heart failure.

Treatment and study plan

Blood sampling

Biological

Blood sampling under a complete aseptic conditions

Primary outcomes

Relation between MicroRNA and HCV

Time frame: 12 months

The ability of estimation of plasma microRNA 21 and 126 to differentiate between uncomplicated and complicated HCV patients

Sponsors and collaborators

Lead sponsor

Benha University

Other

Registry information

Official study title

Plasma Expression Levels of MicroRNA-21 Might Help for Detection of HCV Patients Complicated by Hepatocellular Carcinoma

Important dates

Study start: 2021
Primary completion: 2021
Study completion: 2022
First posted: Jul 8, 2022
Registry last updated: Jul 8, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed